Evidence map›Paper›PMID 38389060›Full record

ArticleBMC infectious diseases2024

Trends of Mycobacterium tuberculosis and Rifampicin resistance in Northwest Ethiopia: Xpert® MTB/RIF assay results from 2015 to 2021.

Sirak Biset, Milto Teferi, Haylemesikel Alamirew, Biniyam Birhanu, Awoke Dessie, Abebe Aschale, Anmaw Haymanot, Selamu Dejenie, Teshager Gebremedhin, Wondwossen Abebe and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Rifampicin-resistantJournal of clinical tuberculosis and other mycobacterial diseases · 2025
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Sirak BisetDepartment of Medical Microbiology, School of Biomedical and Laboratory Sciences, University of Gondar, Gondar, Ethiopia. serbis33@gmail.com.
Milto TeferiSchool of Biomedical and Laboratory Sciences, University of Gondar, Gondar, Ethiopia.
Haylemesikel AlamirewSchool of Biomedical and Laboratory Sciences, University of Gondar, Gondar, Ethiopia.
Biniyam BirhanuSchool of Biomedical and Laboratory Sciences, University of Gondar, Gondar, Ethiopia.
Awoke DessieSchool of Biomedical and Laboratory Sciences, University of Gondar, Gondar, Ethiopia.
Abebe AschaleSchool of Biomedical and Laboratory Sciences, University of Gondar, Gondar, Ethiopia.
Anmaw HaymanotSchool of Biomedical and Laboratory Sciences, University of Gondar, Gondar, Ethiopia.
Selamu DejenieUniversity of Gondar Comprehensive Specialized Hospital, University of Gondar, Gondar, Ethiopia.
Teshager GebremedhinUniversity of Gondar Comprehensive Specialized Hospital, University of Gondar, Gondar, Ethiopia.
Wondwossen AbebeDepartment of Medical Microbiology, School of Biomedical and Laboratory Sciences, University of Gondar, Gondar, Ethiopia.
Gashaw AdaneDepartment of Immunology and Molecular Biology, School of Biomedical and Laboratory Sciences, University of Gondar, Gondar, Ethiopia.
University of Gondar · ET

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTuberculosis (TB) remains one of the leading causes of morbidity and mortality worldwide, particularly in countries with limited resources. The emergence of drug resistance in mycobacterium tuberculosis (MTB), particularly rifampicin (RIF) resistance, hindered TB control efforts. Continuous surveillance and regular monitoring of drug-resistant TB, including rifampicin resistance (RR), are required for effective TB intervention strategies and prevention and control measures.

objectiveDetermine the trend of TB and RR-TB among presumptive TB patients in Northwest Ethiopia.

methodA retrospective study was conducted at the University of Gondar Comprehensive Specialized Hospital (UoG-CSH). The study included TB registration logbook data from all patients who visited the hospital and were tested for MTB using the Xpert® MTB/RIF assay between 2015 and 2021. The SPSS version 26 software was used to enter, clean, and analyze the laboratory-based data.

resultsA total of 18,787 patient results were included, with 93.8% (17,615/18787) of them being successful, meaning they were not invalid, error, or aborted. About 10.5% (1846/17615) of the 17,615 results were MTB-positive, with 7.42% (137/1846) RIF resistant. Age, anti-TB treatment history, and diagnosis year were associated with the presence of MTB and RR-MTB. Tuberculosis (TB) prevalence was higher in productive age groups, whereas RR-TB prevalence was higher in the elderly. Regarding diagnosis year, the prevalence of TB and RR-TB showed a declining trend as the year progressed. While MTB was detected in 12.8% (471/3669) of new and 22.2% (151/679) of re-treatment presumptive TB patients, RR-MTB was detected in 8.5% (40/471) of new and 18.5% (28/151) of re-treatment TB cases.

conclusionThe prevalence of TB and RR-TB in the study area showed a declining trend over the years. While TB was more prevalent in productive age groups (15 to 45 years), RR-TB was more prevalent in older populations (over 45 years), than others. Moreover, patients with a history of anti-TB drug exposure were more likely to be positive for DR-TB, highlighting the need to strengthen DOT programs for proper management of TB treatment.

Indexed as

Antibiotics, AntitubercularMycobacterium tuberculosisTuberculosisTuberculosis, Multidrug-ResistantAdolescentAdultAgedDrug Resistance, BacterialEthiopiaHumansMiddle AgedRetrospective StudiesRifampinYoung AdultAntibiotics, AntitubercularRifampinEthiopiaMulti-drug resistanceRifampicin resistanceTuberculosis

Identifiers

PMID38389060
PMCPMC10882931
OpenAlexW4392050586

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.